Basic Information
| LncRNA/CircRNA Name | ASBEL |
| Synonyms | NA |
| Region | GRCh38_21:17611744-17633199 |
| Ensemble | ENSG00000280594 |
| Refseq | NR_149073 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot etc. |
| Sample | breast cancer tissues, cell lines (MDA-MB-231) |
| Expression Pattern | down-regulated |
| Function Description | LncRNA ASBEL has been identified as an anti-sense transcript of BTG3 (B cell translocation gene 3) gene, which encodes an anti-proliferation protein. Remarkable down-regulation of BTG3 has been reported in triple-negative breast cancer (TNBC). In the present study, a number of single-stranded modified anti-sense DNA oligonucleotides (antago) were designed, synthesized and screened for specific lncRNA ASBEL knockdown. We showed here that anti-ASBEL antago played a significant tumor suppressive role in TNBC by effective down-regulation of lncRNA ASBEL, which in turn led to increased BTG3 expression. The obtained data suggest lncRNA ASBEL as a novel therapeutic target in TNBC. antago3 has a great potential to be an useful therapeutic tool for TNBC treatment through targeting lncRNA ASBEL-related pathway. |
| Pubmed ID | 28552529 |
| Year | 2017 |
| Title | Targeting long non-coding RNA ASBEL with oligonucleotide antagonist for breast cancer therapy |
External Links
| Links for ASBEL | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |